Agilent is a technology company that offer products and services in bio-analytical measurements (life science and chemical analysis) and electronic measurement. In 2009, the bio-analytical measurement unit reviewed in this report accounted for $2.1B (~47%) of the company's $4.5B revenues (FY2009). The bio-analytical measurement business employed approximately 5.1K people worldwide as of October 31, 2009.
Markets: The markets for bio-analytical measurement include life sciences and chemical analysis. Within the life sciences, Agilent focuses on the pharmaceutical, biotechnology, contract research organizations and contract
manufacturing organizations market, and the academic and government market. Its life science markets accounted for approximately 47 percent of revenue from its bio-analytical measurement business in 2009. Within chemical analysis,
Agilent focuses on the petrochemical and chemical, environmental, forensics and homeland security, and bioagriculture and food safety markets. Agilent’s chemical analysis markets accounted for approximately 53 percent of revenue from the bio-analytical measurement business in 2009.
Product areas: Agilent offers measurement instruments, software, consumables and services that enable customers to identify, quantify and analyze the physical and biological properties of substances and products. Agilent is helping
scientists advance basic research, discover the genetic causes of disease and accelerate the discovery and development of biomarkers and therapies. Its integrated workflow solutions deliver accurate, comprehensive data to drive informed decision making, and speed your time to result. The key product categories for the bio-analytical measurement business include: liquid chromatography (LC), gas chromatography, mass spectrometry, microarrays, inductively coupled plasma mass spectrometry, microfluidics, electrophoresis, laboratory automation and robotics, PCR instrumentation, software and informatics, and related bioreagents, consumables and services.
Growth drivers: Agilent continues to see strong market acceptance of the new Agilent 1290 Infinity LC platform, as well as continued momentum in new technologies such as LC mass spectrometry (LC/MS) and microarrays. In addition,
strong demand from the introduction of the SureSelect kits for next-generation sequencing, as well as for the bio-analyzer kit continues to drive growth.
Highlights: The company’s order and revenue results for 2009 in bio-analytical measurement were impacted by the significant downturn in the global economy, although the business was able to sustain growth in key markets, including
food safety, academic and government. Bio-analytical measurement orders in 2009 declined 8 percent when compared to 2008. Agilent had mixed results across geographies with Americas down 11 percent, Europe down 19 percent and Asia and Japan both up 11 percent (vs. 2008). In the chemical analysis business, Agilent continues to see strength in China and food safety markets. In life sciences, Agilent saw sustained demand from academic and government markets, partially offsetting a slowdown in pharmaceutical and biotechnology markets. The Stratagene and Velocity11 acquisitions contributed 5 percentage points of the order growth in 2008, when compared to 2007.
This report profiles Agilent’s bio-analytical division and performs a complete SWOT analysis of the company. |
